Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

MorphoSys AG buy skatcup

MorphoSys AG
Start price
€106.70
25.02.20 / 80%
Target price
€61.00
04.11.21
Performance (%)
-61.92%
End price
€40.63
05.11.21
Summary
This prediction ended on 05.11.21 with a price of €40.63. The BUY prediction by skatcup for MorphoSys AG performed very badly with a performance of -61.92%. skatcup has 80% into this prediction

MorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.

Performance without dividends (%)
Name 1w 1m 1y 3y
MorphoSys AG 0.148% 0.148% 245.840% -10.573%
iShares Core DAX® 1.804% -0.748% 13.168% 16.408%
iShares Nasdaq 100 -0.182% -3.412% 39.976% 43.502%
iShares Nikkei 225® 0.413% -7.381% 18.776% 2.874%
iShares S&P 500 0.664% -1.941% 28.141% 42.155%

According to skatcup what are the pros and cons of MorphoSys AG for the foreseeable future?

Pros
positive Cash Flow expected
Good rating
High Investments for future growth
Some uniques
Small cyclical dependencies
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Capable Management
Innovative
Differentiated customer and product portfolio
Stable Large shareholder and/or long term investor
Top 10 in its market
Cons
High valuation
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Low dividend yield expected
Higher risks for its business

Comments by skatcup for this prediction

In the thread Morphosys AG diskutieren
Prediction Buy
Perf. (%) -61.92%
Target price 140.000
Change
Ends at 04.11.21

Buy mit Kursziel 140,0

skatcup 
0
Report Share
25.02.20
Prediction Buy
Perf. (%) -61.92%
Target price 111.000
Change
Ends at 04.11.21

Kursziel geändert auf 111,0

skatcup 
0
Report Share
15.11.20
Prediction Buy
Perf. (%) -61.92%
Target price 121.000
Change
Ends at 04.11.21

Kursziel geändert auf 121,0

skatcup 
0
Report Share
05.02.21
Prediction Buy
Perf. (%) -61.92%
Target price 111.000
Change
Ends at 04.11.21

Kursziel geändert auf 111,0

skatcup 
0
Report Share
07.06.21
Prediction Buy
Perf. (%) -61.92%
Target price 91.000
Change
Ends at 04.11.21

Kursziel geändert auf 91,0

skatcup 
0
Report Share
10.07.21
Prediction Buy
Perf. (%) -61.92%
Target price 61.000
Change
Ends at 04.11.21

Kursziel geändert auf 61,0

skatcup 
0
Report Share
04.08.21
In the thread Trading Morphosys AG
Prediction Buy
Perf. (%) -61.92%
Target price 61.000
Change
Ends at 04.11.21

Die von skatcup gewählte maximale Laufzeit wurde überschritten

skatcup 
0
Report Share
05.11.21